Phenom Named Strategic Leader in Fosway 9-Grid™ for Talent Acquisition 2024 for Fourth Consecutive Year
Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent Acquisition for the fourth consecutive year, demonstrating the comprehensive nature of its solution and its ability to innovate, drive business impact, and support with customer adoption and satisfaction compared to alternative talent acquisition software solutions. Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers. Strategic Leaders are also recognised by Fosway for having strong market performance and customer advocacy; as a result, they are frequently selected by such organisations and consistently meet their needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530551981/en/
Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent Acquisition for the fourth consecutive year, demonstrating the comprehensive nature of its solution and its ability to innovate, drive business impact, and support with customer adoption and satisfaction compared to alternative talent acquisition software solutions. (Graphic: Business Wire)
The European job market is undergoing a significant transformation. Challenges such as talent shortages and technological disruptions are actively shaping the dynamics of recruitment practices. To navigate this, talent acquisition leaders, sourcers, talent marketers, recruitment events managers, and recruiters must adopt a multifaceted approach that encompasses building alliances, appropriately leveraging and consolidating technology, personalising candidate engagement, maximising utilisation of artificial intelligence and automation, and embracing data insights.
“The TA industry faces many challenges due to a fragmented tech stack, and companies often struggle to streamline their recruitment processes and engage candidates effectively,” said David Wilson, CEO and founder of Fosway Group. “Phenom’s Intelligent Talent Experience platform aims to deliver an effective, data-driven, personalised enterprise solution to these issues. Their continued innovation and customer outcomes are reflected in their position as a Strategic Leader for a fourth successive year.”
The Most Productive, Efficient Organisations Will Define the Decade Ahead
More than 600 global, diverse enterprises use Phenom’s automations, intelligence, and experience to achieve measurable, defensible results, including the ability to:
- Secure 5x more job seekers per month
- Increase chatbot-generated leads by 93%
- Improve application conversion with 85% completion rates
- Accelerate interview scheduling with 88% booked within 24 hours
- Cut 65 days off time to hire
- Save thousands of dollars per hire and reduce dependency on third-parties
“Phenom's fourth consecutive year being recognised as a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent Acquisition reaffirms our commitment to innovation, customer impact, and advocacy,” said John Harrington, Senior Director, Product Marketing at Phenom. “Securing the highest positioning in performance and potential is a testament to our 13+ years in the industry and reflects our ability to partner with global organisations across all industries to address their unique challenges and exceed their goals.”
Leading the Way in Generative AI Adoption and Impact in HR
The advent of generative AI in the past year afforded Phenom a significant opportunity to address the challenges being experienced by its customers with immediate solutions that drive efficiency and productivity outcomes. Since its introduction in 2023, Phenom X+ Generative AI in Phenom’s Intelligent Talent Experience platform has been adopted by over 600 customers, supporting over 60 use cases, and saving HR teams 37,000 hours in the process. Top X+ generative AI use cases and examples of time savings include:
- Email generation, saving Talent CRM users over 6 minutes per email
- Generation of profile summaries, affording 15 hours back to talent acquisition teams each week
- Development of SMS and email campaigns, leading to 35% higher response rates from candidates
Unleashing a Massive Wave of HR Tech Innovation
Phenom continues to innovate by introducing new functionality and capabilities intended to address the top challenges being experienced by talent practitioners today.
2024 Phenom platform innovation highlights include:
- Talent Experience Engine: transforms talent marketers into strategists by leveraging large datasets to create personalised, on-brand campaigns. It enhances efficiency by unifying persona and journey data, enabling content creation, segment identification, personalised journeys, and automated outreach. This comprehensive set of tools optimises engagement and conversion for candidates, employees, and alumni.
- X+ Source: optimises sourcing by segmenting talent pools and creating personalised journeys to attract best-fit candidates. Simply request candidates for a specific role and location, and X+ Source finds the best-fit talent, provides recommendations, summarises key details, and conducts automatic outreach to establish initial contact.
- X+ Workforce Intelligence: connects data from employees, management, HR teams, candidates, and recruiters to provide real-time talent insights for proactive retention and growth. HR teams and managers can identify skills gaps, create personalised development plans, and designate successors based on data to find ideal candidates.
- Talent Marketer Experience: empowers talent marketers to craft personalised content, design campaigns, segment talent, and engage effectively using AI and automation. X+ Agents guide marketers through tasks, enhancing engagement throughout the talent lifecycle via a single, unified platform.
- Talent Leader Experience: provides recruitment managers with organisation-wide insights and individual performance data, including requisition and candidate interaction metrics. X+ Agents offer tailored action plans based on hiring type, enhancing team efficiency and effectiveness.
- X+ Screening: enables fast, intelligent hiring decisions by offering comprehensive insights based on recorded answers, situational judgment questions, and call simulations for all job types.
- Structured Interviews: streamlines interview processes with automated note-taking, question management, and real-time transcription. It enables hiring teams to focus on meaningful candidate interactions while reducing human error and leveraging AI for confident hiring decisions through organised and analysed data.
- Contingent Talent Hiring: helps top brands attract contractors effortlessly via Phenom. Companies can now seamlessly discover and hire temporary workers, with integrated support for Vendor Management Systems and payroll providers for smooth onboarding.
- Events Pro: streamlines event creation to easily target demographics through email, SMS, and registration forms. Personalised virtual event lobbies allow talent to review content, visit booths, and receive automatic event summaries via email.
- Phenom Assessments: have expanded the existing behavioral and language assessments to include motivation and interest assessments to guide early talent to the right jobs.
- X+ Fit Score: enables talent acquisition professionals to extend the typical criteria used to formulate fit scores, or customise the scores in the context of the role.
Companies across EMEA are successfully adopting Phenom’s Intelligent Talent Experience platform to help candidates find and choose the right job faster, employees develop their skills and evolve, recruiters become wildly productive, talent marketers engage with extreme efficiency, talent leaders optimise hiring processes, managers build stronger-performing teams, HR align employee development with company goals, and HRIS easily integrate existing HR tech to create a holistic infrastructure.
On June 6, Phenom is demonstrating its massive wave of recent platform innovations during its HR Innovation Showcase. Register here for the streaming event and see how Phenom continues to innovate, earning its position as a Strategic Leader for the fourth consecutive year.
About the Fosway 9-Grid™
Fosway Group is Europe’s #1 HR industry analyst. The Fosway 9-Grid™ provides a unique assessment of the principal learning and talent supply options available to organisations in EMEA. The analysis is based on extensive independent research and insights from Fosway’s Corporate Research Network of over 250 organisations, including BP, HSBC, PwC, RBS, Sanofi, Shell, and Vodafone. Visit the Fosway website at www.fosway.com.
About Phenom
Phenom has a purpose of helping a billion people find the right work. Through AI-powered talent experiences, employers use Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, talent marketers, talent leaders, hiring managers, HR and HRIS — empowering diverse and global enterprises with innovative products including Phenom X+ Generative AI, Career Site, Chatbot, CMS, Talent CRM, One-Way Interviews, Automated Interview Scheduling, Interview Intelligence, Talent Experience Engine, Campaigns, University Recruiting, Contingent Talent Hiring, Talent Marketplace, Workforce Intelligence, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (4 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530551981/en/
Contact information
Media:
Jennifer Lyons
Phenom
267-379-5066
jennifer.lyons@phenom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
